307 related articles for article (PubMed ID: 24806575)
1. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.
Aprile G; Giampieri R; Bonotto M; Bittoni A; Ongaro E; Cardellino GG; Graziano F; Giuliani F; Fasola G; Cascinu S; Scartozzi M
Expert Opin Investig Drugs; 2014 Jul; 23(7):925-42. PubMed ID: 24806575
[TBL] [Abstract][Full Text] [Related]
2. c-Met targeting in advanced gastric cancer: An open challenge.
Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in gastric cancer.
Thiel A; Ristimäki A
APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
[TBL] [Abstract][Full Text] [Related]
4. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
5. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
6. cMET as a potential therapeutic target in gastric cancer (Review).
Teng L; Lu J
Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Ayyappan S; Prabhakar D; Sharma N
Anticancer Res; 2013 Oct; 33(10):4139-55. PubMed ID: 24122977
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in metastatic esophageal cancer: advances over the past decade.
Mohamed A; El-Rayes B; Khuri FR; Saba NF
Crit Rev Oncol Hematol; 2014 Aug; 91(2):186-96. PubMed ID: 24582516
[TBL] [Abstract][Full Text] [Related]
9. Role of c-mesenchymal-epithelial transition pathway in gastric cancer.
Fioroni I; Dell'Aquila E; Pantano F; Intagliata S; Caricato M; Vincenzi B; Coppola R; Santini D; Tonini G
Expert Opin Pharmacother; 2015 Jun; 16(8):1195-207. PubMed ID: 25881479
[TBL] [Abstract][Full Text] [Related]
10. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Kaur A; Dasanu CA
Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
[TBL] [Abstract][Full Text] [Related]
11. Current status of targeted therapies in advanced gastric cancer.
De Vita F; Giuliani F; Silvestris N; Rossetti S; Pizzolorusso A; Santabarbara G; Galizia G; Colucci G; Ciardiello F; Orditura M
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S29-34. PubMed ID: 22443228
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies in the treatment of gastric cancer.
Ngeow J; Tan IB; Choo SP
Asia Pac J Clin Oncol; 2011 Sep; 7(3):224-35. PubMed ID: 21884434
[TBL] [Abstract][Full Text] [Related]
13. Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer.
Rihawi K; Giampieri R; Scartozzi M; Pusceddu V; Bonotto M; Fasola G; Cascinu S; Aprile G
Expert Opin Investig Drugs; 2015; 24(9):1185-98. PubMed ID: 26044119
[TBL] [Abstract][Full Text] [Related]
14. Investigational therapies targeting the ErbB family in oesophagogastric cancer.
Moorcraft SY; Chau I
Expert Opin Investig Drugs; 2014 Oct; 23(10):1349-63. PubMed ID: 24949530
[TBL] [Abstract][Full Text] [Related]
15. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
Kuo HY; Yeh KH
Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
17. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Wagner AD; Moehler M
Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
[TBL] [Abstract][Full Text] [Related]
18. Emerging mAbs for the treatment of esophagogastric cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2015 Mar; 20(1):63-74. PubMed ID: 25483267
[TBL] [Abstract][Full Text] [Related]
19. Phase I and II clinical trials for gastric cancer.
Khushalani NI
Surg Oncol Clin N Am; 2012 Jan; 21(1):113-28. PubMed ID: 22098835
[TBL] [Abstract][Full Text] [Related]
20. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
